Iovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting
October 11 2017 - 05:33PM
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced
that six abstracts, including one late-breaking abstract
highlighting its TIL therapy, will be presented at the upcoming
Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting from
November 8-12, 2017 in National Harbor, Maryland.
The late-breaking abstract titles are listed on the conference
website at
https://www.sitcancer.org/2017/abstracts/titles/late-breaking.
The other SITC abstract titles are listed on the conference
website under General Categories at
https://www.sitcancer.org/2017/abstracts/titles. The details of the
posters are as follows:
Cellular Therapy Approaches Late-Breaking
Abstract
Title: Novel cryopreserved tumor infiltrating
lymphocytes (LN-144) administered to patients with metastatic
melanoma demonstrates efficacy and tolerability in a multicenter
Phase 2 clinical trialAuthors: Sarnaik, et al.
Poster #: 515Presentation date:
Friday, November 10, 2017
Cellular Therapy Approaches Abstracts
Title: A Cryopreserved TIL Product, LN-144,
Generated with an Abbreviated Method Suitable for High Throughput
Commercial Manufacturing Exhibits Favorable Quality Attributes for
Adoptive Cell TransferAuthors: Wardell, et
al.Poster #: 203Presentation
date: Friday, November 10, 2017
Title: Studies of Key Quality Attributes for
TIL Product, LN-144Authors: Ritthipichai, et
al.Poster #: 194Presentation
date: Saturday, November 11, 2017
Immune Modulation, Cytokines, and Antibodies
Abstract
Title: The T-cell Growth Factor
Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function
of Tumor-Infiltrating T cells in a Novel Process Developed by
IovanceAuthors: Frank, et al. Poster
#: 357Presentation date: Friday, November
10, 2017
Clinical Trials (In Progress) Abstracts
Title: A Phase 2 study to evaluate the safety
and efficacy using autologous tumor infiltrating lymphocytes
(LN-145) in patients with recurrent and/or metastatic squamous cell
carcinoma of the head and neckAuthors: Leidner, et
al.Poster #: 221Presentation
date: Friday, November 10, 2017
Title: A Phase 2, multicenter study to evaluate
the efficacy and safety using autologous tumor infiltrating
lymphocytes (LN-145) in patients with recurrent, metastatic, or
persistent cervical carcinomaAuthors: Jazaeri, et
al.Poster #: 220Presentation
date: Saturday, November 11, 2017
About Iovance Biotherapeutics, Inc. Iovance
Biotherapeutics, Inc. is a clinical-stage biotechnology company
focused on the development of cancer immunotherapy products for the
treatment of various cancers. The Company's lead product candidate
is an adoptive cell therapy using tumor-infiltrating lymphocyte
(TIL) technology being investigated for the treatment of patients
with metastatic melanoma, recurrent and/or metastatic squamous cell
carcinoma of the head and neck and recurrent and metastatic or
persistent cervical cancer. For more information, please
visit http://www.iovance.com.
Forward-Looking Statements Certain matters
discussed in this press release are “forward-looking statements”.
The Company may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. In
particular, the Company’s statements regarding trends and potential
future results are examples of such forward-looking statements. The
forward-looking statements include risks and uncertainties,
including, but not limited to, the success, timing and cost of the
Company’s ongoing clinical trials and anticipated clinical trials
for its current product candidates, including statements regarding
the timing of initiation and completion of the trials; the timing
of and its ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, its product candidates; the strength of
Company’s product pipeline; the successful implementation of the
Company’s research and development programs and collaborations; the
success of the Company’s license or development agreements; the
acceptance by the market of the Company’s product candidates, if
approved; and other factors, including general economic conditions
and regulatory developments, not within the Company’s control. The
factors discussed herein could cause actual results and
developments to be materially different from those expressed in or
implied by such statements. A further list and description of
the Company’s risks, uncertainties and other factors can be found
in the Company’s most recent Annual Report on Form 10-K and the
Company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or www.iovance.com. The forward-looking statements are
made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstance.
Investor Relations Contact: Sarah McCabeStern
Investor Relations, Inc.212-362-1200sarah@sternir.com
Media Relations Contact:Evan Smith/Kotaro
YoshidaFTI Consulting212-850-5622/212-850-5690
evan.smith@fticonsulting.comkotaro.yoshida@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2023 to Mar 2024